AA
PTGX icon

ALPS Advisors’s Protagonist Therapeutics PTGX Stock Holding History

ALPS Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,203
Closed -$1.94M – 1072
2025
Q3 		$1.94M Sell
29,203
-11,017
-27% -$626K 0.01% 387
2025
Q2 		$2.22M Sell
40,220
-12,754
-24% -$612K 0.01% 353
2025
Q1 		$2.56M Sell
52,974
-2,967
-5% -$124K 0.01% 312
2024
Q4 		$2.16M Buy
55,941
+3,909
+8% +$170K 0.01% 339
2024
Q3 		$2.34M Buy
52,032
+6,260
+14% +$253K 0.02% 335
2024
Q2 		$1.59M Buy
45,772
+4,673
+11% +$137K 0.01% 373
2024
Q1 		$1.19M Buy
41,099
+1,027
+3% +$27.9K 0.01% 433
2023
Q4 		$919K Sell
40,072
-2,377
-6% -$41.6K 0.01% 503
2023
Q3 		$708K Buy
42,449
+368
+0.9% +$7.14K 0.01% 550
2023
Q2 		$1.16M Buy
42,081
+9,666
+30% +$242K 0.01% 443
2023
Q1 		$746K Sell
32,415
-934
-3% -$15.7K 0.01% 523
2022
Q4 		$364K Buy
33,349
+6,528
+24% +$55.1K ﹤0.01% 717
2022
Q3 		$226K Sell
26,821
-2,048
-7% -$19.4K ﹤0.01% 986
2022
Q2 		$228K Sell
28,869
-20,891
-42% -$253K ﹤0.01% 976
2022
Q1 		$1.18M Sell
49,760
-5,472
-10% -$154K 0.01% 294
2021
Q4 		$1.89M Buy
+55,232
New +$1.75M 0.02% 295
2018
Q2 		– Sell
-27,468
Closed -$236K – 963
2018
Q1 		$236K Buy
27,468
+4,774
+21% +$89.9K ﹤0.01% 828
2017
Q4 		$472K Buy
+22,694
New +$403K ﹤0.01% 607

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ALPS Advisors's PTGX Position: Q4 2025 in Review

ALPS Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 29,203 shares — an estimated $1.94M sold.

ALPS Advisors first reported a position in PTGX in Q4 2017 and held it in 18 quarters. The position peaked at $2.56M in Q1 2025. 314 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • ALPS Advisors reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 29,203 Protagonist Therapeutics shares in Q4 2025, an estimated $1.94M.
  • ALPS Advisors first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 18 quarters.
  • ALPS Advisors's Protagonist Therapeutics position peaked at $2.56M in Q1 2025.
  • 314 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.